当前位置: 首页 SCI期刊 SCIE期刊 医学 中科院1区 JCRQ1 期刊介绍(非官网)
European Journal Of Cancer

European Journal Of CancerSCIE

国际简称:EUR J CANCER  参考译名:欧洲癌症杂志

  • 中科院分区

    1区

  • CiteScore分区

    Q1

  • JCR分区

    Q1

基本信息:
ISSN:0959-8049
E-ISSN:1879-0852
是否OA:开放
是否预警:否
TOP期刊:是
出版信息:
出版地区:ENGLAND
出版商:Elsevier Ltd
出版语言:English
出版周期:Semimonthly
出版年份:1990
研究方向:肿瘤学-医学
评价信息:
影响因子:7.6
H-index:193
CiteScore指数:11.5
SJR指数:2.501
SNIP指数:1.994
发文数据:
Gold OA文章占比:39.56%
研究类文章占比:90.25%
年发文量:318
自引率:0.0476...
开源占比:0.3075
出版撤稿占比:0
出版国人文章占比:0.02
OA被引用占比:0.2544...
英文简介 期刊介绍 CiteScore数据 中科院SCI分区 JCR分区 发文数据 常见问题

英文简介European Journal Of Cancer期刊介绍

The European Journal of Cancer (including EJC Supplements), is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention. The Journal now has online submission for authors.

期刊简介European Journal Of Cancer期刊介绍

《European Journal Of Cancer》自1990出版以来,是一本医学优秀杂志。致力于发表原创科学研究结果,并为医学各个领域的原创研究提供一个展示平台,以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述,从广泛的视角提供当前感兴趣的研究主题的新见解,或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单,目前已被权威数据库SCIE收录,得到了广泛的认可。

该期刊投稿重要关注点:

Cite Score数据(2024年最新版)European Journal Of Cancer Cite Score数据

  • CiteScore:11.5
  • SJR:2.501
  • SNIP:1.994
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q1 47 / 404

88%

大类:Medicine 小类:Cancer Research Q1 40 / 230

82%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础,针对的是前四年发表的论文的引文。CiteScore的意义在于,它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法,而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区European Journal Of Cancer 中科院分区

中科院 2023年12月升级版 综述期刊:否 Top期刊:是
大类学科 分区 小类学科 分区
医学 1区 ONCOLOGY 肿瘤学 2区

中科院分区表 是以客观数据为基础,运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据,得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次,类似于“优、良、及格”等。最开始,这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区European Journal Of Cancer JCR分区

2023-2024 年最新版
按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 38 / 322

88.4%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 34 / 322

89.6%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异,此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此,JCR将期刊按照学科门类和影响因子分为不同的分区,这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计
  • 国家/地区数量
  • USA703
  • England475
  • France447
  • GERMANY (FED REP GER)410
  • Italy404
  • Netherlands379
  • Spain228
  • Switzerland194
  • Belgium188
  • Japan160

本刊中国学者近年发表论文

  • 1、KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer

    Author: Xu, Jianming; Ying, Jieer; Liu, Rongrui; Wu, Jun; Ye, Feng; Xu, Nong; Zhang, Yanqiao; Zhao, Rusen; Xiang, Xiaojun; Wang, Jianhong; Lin, Xiaoyan; Xu, Huiting; Gao, Shegan; Luo, Suxia; Guo, Baohong; Li, Xionghui; Su, Yangzhi; Wang, Qian

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 1-12. DOI: 10.1016/j.ejca.2022.10.004

  • 2、Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

    Author: Swain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 70-81. DOI: 10.1016/j.ejca.2022.09.024

  • 3、Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)

    Author: Sheng, Xinan; Ye, DingWei; Zhou, Aiping; Yao, Xin; Luo, Hong; He, Zhisong; Wang, Zengjun; Zhao, Yingchao; Ji, Zhigang; Zou, Qing; He, Chaohong; Guo, Jianming; Tu, Xinhua; Liu, Ziling; Shi, Benkang; Liu, Ben; Chen, Peng; Wei, Qiang; Hu, Zhiquan; Zhang, Yanqiao; Jiang, Kui; Zhou, Fangjian; Wu, Dapeng; Fu, Cheng; Li, Xingya; Wu, Bin; Wang, Lijie; Qin, Shukui; Li, Gang; Liu, Yunpeng; Guo, Hongqian; Chen, Kehe; Zhang, Dahong; Wang, Gongxian; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Guo, Jun

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 205-215. DOI: 10.1016/j.ejca.2022.10.025

  • 4、Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases

    Author: Guo, Ye; Zhang, Weijie; Ying, Jieer; Zhang, Yanqiao; Pan, Yueyin; Qiu, Wensheng; Fan, Qingxia; Xu, Qi; Ma, Yue; Wang, Gang; Guo, Jing; Su, Weiguo; Fan, Songhua; Tan, Panfeng; Wang, Yan; Luo, Yang; Zhou, Hui; Li, Jin

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 181, Issue , pp. 26-37. DOI: 10.1016/j.ejca.2022.12.004

  • 5、Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    Author: Cueva, Juan F.; Palacio, Isabel; Churruca, Cristina; Herrero, Ana; Pardo, Beatriz; Constenla, Manuel; Santaballa, Ana; Manso, Luis; Estevez, Purificacin; Maximiano, Constanza; Legeren, Marta; Marquina, Gloria; de Juan, Ana; Quindos, Maria; Sanchez, Luisa; Barquin, Arantzazu; Fernandez, Isaura; Martin, Cristina; Juarez, Asuncin; Martin, Teresa; Garcia, Yolanda; Yubero, Alfonso; Gallego, Alejandro; Bueno, Alejandro Martinez; Guerra, Eva; Gonzalez-Martin, Antonio

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 3-14. DOI: 10.1016/j.ejca.2022.12.023

  • 6、Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial

    Author: Wang, Xuan; Wu, Xiaowen; Yang, Yue; Xu, Weiran; Tian, Hui; Lian, Bin; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Zhou, Li; Mao, Lili; Li, Siming; Tang, Bixia; Yan, Xieqiao; Bai, Xue; Guo, Jun; Cui, ChuanLiang

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 57-65. DOI: 10.1016/j.ejca.2022.12.027

  • 7、First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

    Author: Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I.; Penrod, John R.; Carbone, David P.

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 183, Issue , pp. 174-187. DOI: 10.1016/j.ejca.2023.01.015

  • 8、OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Author: Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 39-47. DOI: 10.1016/j.ejca.2023.01.031

投稿常见问题

通讯方式:ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB。